Tianda Pharmaceuticals Ltd. (HK:0455)
:0455
Want to see HK:0455 full AI Analyst Report?
0455 Stock Chart & Stats
HK$0.13
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.13
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.09 - HK$0.22
Previous CloseN/A
Volume4.00K
Average Volume (3M)84.94K
Market Cap
HK$195.65M
Enterprise ValueHK$263.50M
Total Cash (Recent Filing)HK$64.81M
Total Debt (Recent Filing)HK$132.66M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,150,041,700
10 Day Avg. Volume115,400
30 Day Avg. Volume84,945
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.61
Price to Sales (P/S)0.86
P/FCF Ratio99.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageModerate debt-to-equity gives the company financial flexibility and lower interest burden versus highly leveraged peers. Over a 2–6 month horizon this reduces refinancing pressure, preserves capacity to fund operations or targeted investments, and limits default risk while profits remain under repair.
Return To Positive Operating Cash FlowResuming positive operating cash flow and modest free cash flow in 2025 improves near-term liquidity and reduces reliance on external financing. If sustained, this strengthens the firm’s ability to fund R&D, working capital or debt service, improving survival prospects and strategic optionality.
Relatively Healthy Gross MarginsGross margins in the low-40s indicate underlying product-level profitability and potential pricing or cost advantages relative to lower-margin peers. Even with compression, healthy gross margins provide a foundation for recovery if revenue stabilizes, enabling operating leverage to return faster.
Bears Say
Persistent Losses And Widening Net MarginSustained and worsening net losses materially erode retained earnings and constrain reinvestment. Over several months this limits capacity to scale commercial efforts or R&D, increases scrutiny from lenders and investors, and raises the probability management must pursue dilutive financing or cost cuts to survive.
Declining Revenue And Margin CompressionFalling sales plus compressed gross margins reduce the ability to achieve operating leverage, making fixed costs harder to cover. This structural revenue shrinkage undermines sustainable profitability and makes recovery harder, increasing execution risk over the medium term.
Erosion Of Shareholder Equity And Negative ROEOngoing losses have materially reduced shareholders' equity, weakening the capital buffer against shocks and raising dilution risk if external capital is needed. Persistently negative ROE signals that capital is not generating returns, which constrains strategic options and may raise funding costs.
Tianda Pharmaceuticals Ltd. News
0455 FAQ
What was Tianda Pharmaceuticals Ltd.’s price range in the past 12 months?
Tianda Pharmaceuticals Ltd. lowest stock price was HK$0.09 and its highest was HK$0.21 in the past 12 months.
What is Tianda Pharmaceuticals Ltd.’s market cap?
Tianda Pharmaceuticals Ltd.’s market cap is HK$195.65M.
When is Tianda Pharmaceuticals Ltd.’s upcoming earnings report date?
Tianda Pharmaceuticals Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 104 days.
How were Tianda Pharmaceuticals Ltd.’s earnings last quarter?
Tianda Pharmaceuticals Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.017.
Is Tianda Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Tianda Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Tianda Pharmaceuticals Ltd. pay dividends?
Tianda Pharmaceuticals Ltd. does not currently pay dividends.
What is Tianda Pharmaceuticals Ltd.’s EPS estimate?
Tianda Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianda Pharmaceuticals Ltd. have?
Tianda Pharmaceuticals Ltd. has 2,150,041,700 shares outstanding.
What happened to Tianda Pharmaceuticals Ltd.’s price movement after its last earnings report?
Tianda Pharmaceuticals Ltd. reported an EPS of -HK$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tianda Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:0455
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tianda Pharmaceuticals Ltd.
Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. Its product range includes Chinese medicines, chemical drugs, biological and health products, and medical appliances covering the area of cardio-cerebrovascular, pediatric, anti-flu and respiratory, anti-infection, detoxification, urological agents, and others. The company offers its health products under the Herb Valley and Tuokang brands. It also engages in the sale and wholesale of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicines; provision of Chinese medical services; and trading of agricultural by-products. The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. The company was incorporated in 1992 and is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.
Technical Analysis
Wai Yuen Tong Medicine Holdings Limited
―
China NT Pharma Group Co., Ltd.
―
Fusen Pharmaceutical Co., Ltd.
―
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
―
Huakang Biomedical Holdings Company Limited
―